

Today	r'c da	to.	Intended date of injec	ction	
Ioua	y s ua	ice.	intended date of inject	cuoii.	

Prior Authorization Form – Nucala®

Buy-and-bill requests for this drug should be submitted through NaviNet®.

ONLY COMPLETED DECO	LIESTS WILL BE DEVIEWED									
ONLY COMPLETED REQUESTS WILL BE REVIEWED. Check one: New start Continued treatment										
circument and the start and a continued treatment										
Patient information (please print)	Physician information (please print)									
Patient name	Prescribing physician									
Address	Office address									
City, state, ZIP	City, state, ZIP									
Patient telephone #	Office contact									
Patient ID	Office telephone #									
Date of birth	Fax #	NPI								
This drug will be delivered to the requesting physician.										
** A copy of the prescription must accom	pany the medication reques	t for deliver	y.**							
1) Diagnosis for drug requested (must include ICD-10):			_							
2) Patient medical information										
For severe asthma with an eosinophilic phenotype										
a. Is the patient 12 years of age or older?			☐ Yes	☐ No						
 Have results of complete blood count (CBC) drawn at the in least 150 cells/microliter, or eosinophils of at least 300 cells/ If yes, please fax this documentation along with this form. 	•	hils of at	☐Yes	☐ No						
c. Is the patient currently receiving treatment that does not m Nucala will be used as additional maintenance therapy?	Is the patient currently receiving treatment that does not maintain adequate control of asthma, and Nucala will be used as additional maintenance therapy?									
 Does the patient's current treatment include high-dose inhomits or without oral corticosteroids, in combination with an Check all that apply, and list the drug/dose/duration on the 		☐Yes	□No							
☐ Long-acting beta agonist (LABA) (e.g., Foradil, Serevent®);										
☐ Combination high-dose ICE and LABA (e.g., Advair®, Symbicort®);										
☐ Leukotriene receptor antagonist (e.g., Singulair®);										
☐ Theophylline;										
☐ Other;										
\square The patient is intolerant to or has a contraindication to these agents.										
(continued on next page)										



Prior Authorization Form – Nucala® (continued)

For relapsed or refractory eosinophilic granulomatosis with polyangiitis (EGPA)							
a. Is the patient 18 years of age or older?	☐Yes	□No					
b. Does the patient have a history of asthma or a current asthma condition?	☐Yes	□No					
c. Have results of complete blood count (CBC) shown >10% of leukocytes or an absolute eosinophil count >1,000 cells/mm³ (or >1 x 10°/L) in the past six months? If yes, please fax this documentation along with this form.	☐Yes	□No					
 d. Does the patient currently have any of the following features typical of EGPA? (check all that are currently present) 	☐Yes	□No					
☐ Biopsy showing histopathological evidence of eosinophilic vasculitis, perivascular eosinophilic infiltration, or eosinophil-rich granulomatous inflammation							
☐ Neuropathy							
☐ Pulmonary infiltrates							
☐ Sinonasal abnormality							
☐ Cardiomyopathy							
☐ Glomerulonephritis							
☐ Alveolar hemorrhage							
☐ Palpable purpura							
☐ Positive test for antineutrophil cytoplasmic antibody (ANCA)							
e. Does the patient's current treatment include oral corticosteroids? If no, is the patient intolerant to or have a contraindication to these agents? Intolerance Contraindication	☐ Yes	□No					
Reason for intolerance or contraindication?							
) Prescription information							
Quantity refill x month(s)							
Instructions (include dose) every day(s)/ week(s)/ m	nonth(s)						
Physician's signature							

4/15/2018 #08.01.23

Please fax this completed form to 215-761-9580.